Yun Chang Li

US Patent:

20210139986, May 13, 2021

Filed:

Dec 31, 2020

Appl. No.:

17/139266

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12Q 1/6881
C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20200080152, Mar 12, 2020

Filed:

Aug 20, 2019

Appl. No.:

16/545469

Inventors:

- Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
Brendan Keating - Philadelphia PA, US

International Classification:

C12Q 1/6883

Abstract:

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

US Patent:

20190002980, Jan 3, 2019

Filed:

Sep 10, 2018

Appl. No.:

16/126581

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12Q 1/6881
C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20170283872, Oct 5, 2017

Filed:

Apr 3, 2017

Appl. No.:

15/477873

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12Q 1/68
C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20170051351, Feb 23, 2017

Filed:

Aug 19, 2016

Appl. No.:

15/242091

Inventors:

- Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
Brendan Keating - Philadelphia PA, US

International Classification:

C12Q 1/68

Abstract:

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

US Patent:

20170051352, Feb 23, 2017

Filed:

Aug 19, 2016

Appl. No.:

15/242210

Inventors:

- Philadelphia PA, US
Charlly Kao - Philadelphia PA, US
Christopher Cardinale - Philadelphia PA, US
Rahul Pandey - Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US

International Classification:

C12Q 1/68
C07K 16/24
C12N 15/113

Abstract:

The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.

US Patent:

20150376259, Dec 31, 2015

Filed:

Jun 30, 2015

Appl. No.:

14/754940

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.